-
-
NCT00210821
-
Primary Citation
Trial has yet to be published
-
Data Specification
Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous SystemProduct ClassAntiepilepticsPharmacological SubgroupAntiepilepticsChemical SubgroupOther AntiepilepticsCondition StudiedMigraine Disorders
Sponsor Protocol NumberCAPSS-277Enrollment347Data PartnerJohnson & Johnson% Female84.9%Mean/Median Age (Years)38.8% White84.6%
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0896 : Association Between Monthly Migraine Days and Disability Outcomes
- 2022-4952 : Topiramate versus oral gepants in the treatment of patients with migraine: a matching adjusted indirect comparison
- 2020-4276 : Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis
